02.06.2016 | comment
Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?
Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2016
Einloggen, um Zugang zu erhalten